Myocet liposomal (previously Myocet)

RSS

doxorubicin

Authorised
This medicine is authorised for use in the European Union.

Overview

Myocet liposomal is a cancer medicine for use with cyclophosphamide (another cancer medicine) to treat women with metastatic breast cancer. ‘Metastatic’ means that the cancer has spread to other parts of the body.

Myocet liposomal contains the active substance doxorubicin.

This EPAR was last updated on 04/02/2020

Authorisation details

Product details
Name
Myocet liposomal (previously Myocet)
Agency product number
EMEA/H/C/000297
Active substance
doxorubicin hydrochloride
International non-proprietary name (INN) or common name
doxorubicin
Therapeutic area (MeSH)
Breast Neoplasms
Anatomical therapeutic chemical (ATC) code
L01DB01
Publication details
Marketing-authorisation holder
Teva B.V.
Revision
21
Date of issue of marketing authorisation valid throughout the European Union
13/07/2000
Contact address

Swensweg 5
2031GA Haarlem
The Netherlands

Product information

24/10/2019 Myocet liposomal (previously Myocet) - EMEA/H/C/000297 - IAIN/0060

Contents

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Antineoplastic agents

Therapeutic indication

Myocet liposomal, in combination with cyclophosphamide, is indicated for the first-line treatment of metastatic breast cancer in adult women.

Assessment history

How useful was this page?

Add your rating